Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
FOLFOX plus PAC(ip)
DRUG
2 trials
Sponsors
Fujian Cancer Hospital
Conditions
Gastric Cancer
Malignant Neoplasm of Stomach Stage IV
Phase 2
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
Completed
NCT02845908
Fujian Cancer Hospital
Malignant Neoplasm of Stomach Stage IV
Start: 2015-11-30
End: 2020-05-31
Updated: 2021-04-23
POF Versus FOLFOX Plus IP Paclitaxel in AGC
NCT04155671
Fujian Cancer Hospital
Gastric Cancer
Start: 2019-12-01
End: 2023-06-30
Target: 260
Updated: 2019-11-07
Related Papers
Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.
Journal of Clinical Oncology
2021-05-20
2 citations
POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.
Journal of Clinical Oncology
2019-05-20
10 citations
FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.
Journal of Clinical Oncology
2019-01-29
2 citations
A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): A feasibility analysis.
Journal of Clinical Oncology
2017-02-01
1 citations